CYP 2.00% 25.5¢ cynata therapeutics limited

Ann: Cynata Expands trial in COVID-19 & Respiratory Failure, page-166

  1. 1,181 Posts.
    lightbulb Created with Sketch. 3879

    The MEseNchymal coviD-19 Trial: MSCs in Adults With Respiratory Failure Due to COVID-19 or Another Underlying Cause (MEND)

    Now (yesterday) officially updated with VIC based hospitals also recruiting:

    https://hotcopper.com.au/data/attachments/3199/3199063-4c1553f66ff14ed73bad97c2c7e347dd.jpg

    https://clinicaltrials.gov/ct2/show/NCT04537351
 
watchlist Created with Sketch. Add CYP (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.